#BEGIN_DRUGCARD DB00266

# AHFS_Codes:
Not Available

# ATC_Codes:
B01AA01

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Acadyl
Acavyl
Antitrombosin
Baracoumin
Cuma
Cumid
Dicoumal
Dicuman
Dicumaol R
Dicumarine
Dicumol
Dikumarol
Dufalone
Kumoran
Melitoxin
Temparin
Trombosan

# CAS_Registry_Number:
66-76-2

# ChEBI_ID:
4513

# Chemical_Formula:
C19H12O6

# Chemical_IUPAC_Name:
4-hydroxy-3-[(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl]-2H-chromen-2-one

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases. [PubChem]

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Anticoagulants
Enzyme Inhibitors
Uncoupling Agents

# Drug_Interactions:
Acetaminophen	Acetaminophen may increase the anticoagulant effect of dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if acetaminophen is initiated, discontinued or dose changed.
Acetohexamide	Dicumarol may increase the effect of sulfonylurea, acetohexamide.
Acetylsalicylic acid	Acetylsalicylic acid increases effect of the anticoagulant, dicumarol.
Allopurinol	Allopurinol may increase the anticoagulant effect of dicumarol.
Aminoglutethimide	Aminoglutethimide may decrease the anticoagulant effect of dicumarol.
Amiodarone	Amiodarone may increase the anticoagulant effect of dicumarol.
Amprenavir	Amprenavir may increase the anticoagulant effect of dicumarol by increasing its serum concentration.
Aprepitant	Aprepitant may decrease the anticoagulant effect of dicumarol by decreasing its serum concentration.
Atazanavir	The protease inhibitor, atazanavir, may increase the anticoagulant effect of dicumarol.
Azathioprine	Azathioprine may decrease the anticoagulant effect of dicumarol.
Azithromycin	Azithromycin may increase the anticoagulant effect of dicumarol by increasing its serum concentration.
Betamethasone	The corticosteroid, betamethasone, alters the anticoagulant effect of dicumarol.
Bosentan	Bosentan may decrease the anticoagulant effect of dicumarol by increasing its metabolism.
Capecitabine	Capecitabine may increase the anticoagulant effect of dicumarol by increasing its serum concentration.
Carbamazepine	Carbamazepine may decrease the anticoagulant effect of dicumarol by decreasing its serum concentration.
Cefotetan	The cephalosporin, cefotetan, may increase the anticoagulant effect of dicumarol.
Cefoxitin	The cephalosporin, cefoxitin, may increase the anticoagulant effect of dicumarol.
Ceftriaxone	The cephalosporin, ceftriaxone, may increase the anticoagulant effect of dicumarol.
Celecoxib	Celecoxib may increase the anticoagulant effect of dicumarol.
Chlorpropamide	Dicumarol may increase the effect of sulfonylurea, chlorpropamide.
Cholestyramine	The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of dicumarol by decreasing its absorption.
Cimetidine	Cimetidine may increase the anticoagulant effect of dicumarol.
Ciprofloxacin	The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of dicumarol.
Cisapride	Cisapride may increase the anticoagulant effect of dicumarol.
Citalopram	The SSRI, citalopram, increases the effect of anticoagulant, dicumarol.
Clarithromycin	The macrolide, clarithromycin, may increase the anticoagulant effect of dicumarol.
Clofibrate	The fibrate increases the anticoagulant effect
Colestipol	The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of dicumarol by decreasing its absorption.
Cyclophosphamide	The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of dicumarol.
Danazol	The androgen, danazol, may increase the anticoagulant effect of dicumarol.
Demeclocycline	The tetracycline, demeclocycline, may increase the anticoagulant effect of dicumarol.
Dexamethasone	The corticosteroid, dexamethasone, alters the anticoagulant effect of dicumarol.
Dextrothyroxine	The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of dicumarol.
Diclofenac	The NSAID, diclofenac, may increase the anticoagulant effect of dicumarol.
Dicloxacillin	Dicloxacillin may decrease the anticoagulant effect of dicumarol.
Diflunisal	The NSAID, diflunisal, may increase the anticoagulant effect of dicumarol.
Disulfiram	Disulfiram may increase the anticoagulant effect of dicumarol.
Doxycycline	The tetracycline, doxycycline, may increase the anticoagulant effect of dicumarol.
Erythromycin	The macrolide, erythromycin, may increase the anticoagulant effect of dicumarol..
Ethchlorvynol	Ethchlorvynol may decrease the anticoagulant effect of dicumarol.
Ethinyl Estradiol	Increased thrombotic risk due to estrogen
Etodolac	The NSAID, etodolac, may increase the anticoagulant effect of dicumarol.
Etoricoxib	Etoricoxib may increase the anticoagulant effect of dicumarol.
Fenofibrate	Fenofibrate may increase the anticoagulant effect of dicumarol.
Fenoprofen	The NSAID, fenoprofen, may increase the anticoagulant effect of dicumarol.
Fluconazole	Fluconazole may increase the serum concentration of dicumarol by decreasing its metabolism.
Fludrocortisone	The corticosteroid, fludrocortisone, alters the anticoagulant effect of dicumarol.
Fluorouracil	The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of dicumarol.
Fluoxetine	The SSRI, fluoxetine, increases the effect of anticoagulant, dicumarol.
Fluoxymesterone	The androgen, fluoxymesterone, may increase the anticoagulant effect of dicumarol.
Flurbiprofen	The NSAID, flurbiprofen, may increase the anticoagulant effect of dicumarol.
Fluvastatin	Fluvastatin may increase the anticoagulant effect of dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if fluvastatin if initiated, discontinued or dose changed.
Fluvoxamine	Fluvoxamine may increase the anticoagulant effect of dicumarol by increasing its serum concentration.
Fosamprenavir	The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of dicumarol.
Fosphenytoin	Increased hydantoin levels and risk of bleeding
Gefitinib	Gefitinib may increase the anticoagulant effect of dicumarol.
Gemcitabine	Gemcitabine may increase the anticoagulant effect of dicumarol.
Gemfibrozil	Gemfibrozil may increase the anticoagulant effect of dicumarol.
Gliclazide	Dicumarol may increase the effect of sulfonylurea, gliclazide.
Glutethimide	Glutethimide may decrease the anticoagulant effect of dicumarol.
Glyburide	Dicumarol may increase the effect of sulfonylurea, glibenclamide.
Griseofulvin	Griseofulvin may decrease the anticoagulant effect of dicumarol.
Hydrocortisone	The corticosteroid, hydrocortisone, alters the anticoagulant effect of dicumarol.
Ibuprofen	The NSAID, ibuprofen, may increase the anticoagulant effect of dicumarol.
Imatinib	Imatinib may increase the anticoagulant effect of dicumarol.
Indinavir	The protease inhibitor, indinavir, may increase the anticoagulant effect of dicumarol.
Indomethacin	The NSAID, indomethacin, may increase the anticoagulant effect of dicumarol.
Isoniazid	Isoniazid may increase the anticoagulant effect of dicumarol.
Itraconazole	Itraconazole may increase the anticoagulant effect of dicumarol.
Ketoconazole	Ketoconazole may increase the anticoagulant effect of dicumarol.
Ketoprofen	The NSAID, ketoprofen, may increase the anticoagulant effect of dicumarol.
Ketorolac	The NSAID, ketorolac, may increase the anticoagulant effect of dicumarol.
Leflunomide	Leflunomide may increase the anticoagulant effect of dicumarol.
Levamisole	Levamisole may increase the anticoagulant effect of dicumarol.
Levofloxacin	The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of dicumarol.
Levothyroxine	The thyroid hormone, levothyroxine, increase the anticoagulant effect of dicumarol.
Lovastatin	Lovastatin may increase the anticoagulant effect dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if lovastatin is initiated, discontinued or dose changed.
Lumiracoxib	Lumiracoxib may increase the anticoagulant effect of dicumarol.
Medroxyprogesterone	Medroxyprogesterone may increase the anticoagulant effect of dicumarol.
Mefenamic acid	The NSAID, mefanamic acid, may increase the anticoagulant effect of dicumarol.
Mefloquine	Mefloquine may increase the anticoagulant effect of dicumarol.
Meloxicam	Meloxicam may increase the anticoagulant effect of dicumarol.
Mercaptopurine	Mercaptopurine may decrease the anticoagulant effect of dicumarol.
Methimazole	The antithyroid agent, methimazole, may decrease the anticoagulant effect of dicumarol.
Metronidazole	Metronidazole may increase the anticoagulant effect of dicumarol.
Miconazole	Miconazole may increase the serum concentration of dicumarol by decreasing its metabolism.
Minocycline	The tetracycline, minocycline, may increase the anticoagulant effect of dicumarol.
Mitotane	Mitotane may decrease the anticoagulant effect of dicumarol.
Moxifloxacin	The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of dicumarol.
Nabumetone	The NSAID, nabumetone, may increase the anticoagulant effect of dicumarol.
Nalidixic Acid	The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of dicumarol.
Naproxen	The NSAID, naproxen, may increase the anticoagulant effect of dicumarol.
Nelfinavir	The protease inhibitor, nelfinavir, may increase the anticoagulant effect of dicumarol.
Nevirapine	Nevirapine may decrease the anticoagulant effect of dicumarol.
Norfloxacin	The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of dicumarol.
Ofloxacin	The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of dicumarol.
Orlistat	Orlistat may increase the anticoagulant effect of dicumarol.
Oxaprozin	The NSAID, oxaprozin, may increase the anticoagulant effect of dicumarol.
Oxyphenbutazone	The NSAID, oxyphenbutazone, may increase the anticoagulant effect of dicumarol.
Paroxetine	The SSRI, paroxetine, increases the effect of anticoagulant, dicumarol.
Pentoxifylline	Pentoxifylline may increase the anticoagulant effect of dicumarol.
Phenobarbital	The barbiturate, phenobarbital, decreases the anticoagulant effect, dicumarol.
Phenylbutazone	The NSAID, phenylbutazone, may increase the anticoagulant effect of dicumarol.
Phenytoin	Increased hydantoin levels and risk of bleeding
Piroxicam	The NSAID, piroxicam, may increase the anticoagulant effect of dicumarol.
Prednisolone	The corticosteroid, prednisolone, alters the anticoagulant effect of dicumarol.
Prednisone	The corticosteroid, prednisone, alters the anticoagulant effect of dicumarol.
Primidone	The barbiturate, primidone, decreases the anticoagulant effect, dicumarol.
Propafenone	Propafenone may increase the anticoagulant effect of dicumarol.
Propoxyphene	Propoxyphene may increase the anticoagulant effect of dicumarol.
Propylthiouracil	The anti-thyroid agent, propylthiouracil, may decrease the anticoagulant effect of dicumarol.
Quinidine	Quinidine may increase the anticoagulant effect of dicumarol.
Quinine	Quinine may increase the anticoagulant effect of dicumarol.
Ranitidine	Ranitidine may increase the anticoagulant effect of dicumarol. (Conflicting evidence)
Rifabutin	Rifabutin may decrease the anticoagulant effect of dicumarol.
Rifampin	Rifampin may decrease the anticoagulant effect of dicumarol.
Telithromycin	Telithromycin may increase the anticoagulant effect of dicumarol.
Tenoxicam	The NSAID, tenoxicam, may increase the anticoagulant effect of dicumarol.
Testosterone	The androgen may increase the anticoagulant effect of dicumarol.
Tetracycline	Tetracycline may increase the anticoagulant effect of dicumarol.
Tigecycline	Tigecycline may increase the anticoagulant effect of dicumarol.
Triamcinolone	The corticosteroid, triamcinolone, alters the anticoagulant effect of dicumarol.

# Drug_Reference:
12880296	Thanos CG, Liu Z, Reineke J, Edwards E, Mathiowitz E: Improving relative bioavailability of dicumarol by reducing particle size and adding the adhesive poly(fumaric-co-sebacic) anhydride. Pharm Res. 2003 Jul;20(7):1093-100.
14500388	Cullen JJ, Hinkhouse MM, Grady M, Gaut AW, Liu J, Zhang YP, Weydert CJ, Domann FE, Oberley LW: Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. Cancer Res. 2003 Sep 1;63(17):5513-20.
15511084	Mironov AA, Colanzi A, Polishchuk RS, Beznoussenko GV, Mironov AA Jr, Fusella A, Di Tullio G, Silletta MG, Corda D, De Matteis MA, Luini A: Dicumarol, an inhibitor of ADP-ribosylation of CtBP3/BARS, fragments golgi non-compact tubular zones and inhibits intra-golgi transport. Eur J Cell Biol. 2004 Jul;83(6):263-79.
15639223	Abdelmohsen K, Stuhlmann D, Daubrawa F, Klotz LO: Dicumarol is a potent reversible inhibitor of gap junctional intercellular communication. Arch Biochem Biophys. 2005 Feb 15;434(2):241-7.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
2.07

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
128 mg/L

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Dicumarol

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,20-21H,9H2

# InChI_Key:
InChIKey=DOBMPNYZJYQDGZ-UHFFFAOYSA-N

# Indication:
For decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis.

# KEGG_Compound_ID:
C00796

# KEGG_Drug_ID:
D03798

# LIMS_Drug_ID:
266

# Mechanism_Of_Action:
Dicumarol inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Depression of three of the four vitamin K-dependent coagulation factors (factors II, VII, and X) results in decresed prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots.

# Melting_Point:
290 °C

# Molecular_Weight_Avg:
336.295

# Molecular_Weight_Mono:
336.063388116

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Dicumarol Pathway	SMP00270

# PharmGKB_ID:
PA449298

# Pharmacology:
Dicumarol is an coumarin-like compound found in sweet clover. It is used as an oral anticoagulant and acts by inhibiting the hepatic synthesis of vitamin K-dependent coagulation factors (prothrombin and factors VII, IX, and X). It is also used in biochemical experiments as an inhibitor of reductases.

# Predicted_LogP_Hydrophobicity:
1.54

# Predicted_LogS:
-3.7

# Predicted_Water_Solubility:
6.62e-02 g/l

# Primary_Accession_No:
DB00266

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00761

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Bis-Hydroxycoumarin
Bishydroxycoumarin
Dicoumarin
Dicoumarol

# Synthesis_Reference:
Not Available

# Toxicity:
LD<sub>50</sub>=233 mg/kg (orally in mice); LD<sub>50</sub>=250 mg/kg (orally in rats)

# Update_Date:
2013-02-08 16:19:13 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Dicumarol

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2C9

# Phase_1_Metabolizing_Enzyme_1_ID:
4757

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2C9

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P11712

# Drug_Target_1_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2424118	Wallin R, Patrick SD, Ballard JO: Vitamin K antagonism of coumarin intoxication in the rat. Thromb Haemost. 1986 Apr 30;55(2):235-9.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
VKORC1

# Drug_Target_1_GenBank_ID_Gene:
AY423044

# Drug_Target_1_GenBank_ID_Protein:
40217983

# Drug_Target_1_GeneCard_ID:
VKORC1

# Drug_Target_1_Gene_Name:
VKORC1

# Drug_Target_1_Gene_Sequence:
>492 bp
ATGGGCAGCACCTGGGGGAGCCCTGGCTGGGTGCGGCTCGCTCTTTGCCTGACGGGCTTA
GTGCTCTCGCTCTACGCGCTGCACGTGAAGGCGGCGCGCGCCCGGGACCGGGATTACCGC
GCGCTCTGCGACGTGGGCACCGCCATCAGCTGTTCGCGCGTCTTCTCCTCCAGGTGGGGC
AGGGGTTTCGGGCTGGTGGAGCATGTGCTGGGACAGGACAGCATCCTCAATCAATCCAAC
AGCATATTCGGTTGCATCTTCTACACACTACAGCTATTGTTAGGTTGCCTGCGGACACGC
TGGGCCTCTGTCCTGATGCTGCTGAGCTCCCTGGTGTCTCTCGCTGGTTCTGTCTACCTG
GCCTGGATCCTGTTCTTCGTGCTCTATGATTTCTGCATTGTTTGTATCACCACCTATGCT
ATCAACGTGAGCCTGATGTGGCTCAGTTTCCGGAAGGTCCAAGAACCCCAGGGCAAGGCT
AAGAGGCACTGA

# Drug_Target_1_General_Function:
Involved in vitamin-K-epoxide reductase (warfarin-sensitive) activity

# Drug_Target_1_General_References:
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.

# Drug_Target_1_HGNC_ID:
HGNC:23663

# Drug_Target_1_HPRD_ID:
10540

# Drug_Target_1_ID:
787

# Drug_Target_1_Locus:
16p11.2

# Drug_Target_1_Molecular_Weight:
18235

# Drug_Target_1_Name:
Vitamin K epoxide reductase complex subunit 1

# Drug_Target_1_Number_of_Residues:
163

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF07884	VKOR

# Drug_Target_1_Protein_Sequence:
>Vitamin K epoxide reductase complex subunit 1
MGSTWGSPGWVRLALCLTGLVLSLYALHVKAARARDRDYRALCDVGTAISCSRVFSSRWG
RGFGLVEHVLGQDSILNQSNSIFGCIFYTLQLLLGCLRTRWASVLMLLSSLVSLAGSVYL
AWILFFVLYDFCIVCITTYAINVSLMWLSFRKVQEPQGKAKRH

# Drug_Target_1_Reaction:
2-methyl-3-phytyl-1,4-naphthoquinone + oxidized dithiothreitol = 2,3-epoxy-2,3-dihydro-2-methyl-3-phytyl-1,4-naphthoquinone + 1,4-dithiothreitol

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K

# Drug_Target_1_SwissProt_ID:
Q9BQB6

# Drug_Target_1_SwissProt_Name:
VKOR1_HUMAN

# Drug_Target_1_Synonyms:
EC 1.1.4.1
Vitamin K1 2,3-epoxide reductase subunit 1

# Drug_Target_1_Theoretical_pI:
9.58

# Drug_Target_1_Transmembrane_Regions:
9-29
101-123
127-149

# Drug_Target_2_Cellular_Location:
Cytoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10419545	Chen S, Wu K, Zhang D, Sherman M, Knox R, Yang CS: Molecular characterization of binding of substrates and inhibitors to DT-diaphorase: combined approach involving site-directed mutagenesis, inhibitor-binding analysis, and computer modeling. Mol Pharmacol. 1999 Aug;56(2):272-8.
10683249	Jaiswal AK: Characterization and partial purification of microsomal NAD(P)H:quinone oxidoreductases. Arch Biochem Biophys. 2000 Mar 1;375(1):62-8.
10755406	Joseph P, Jaiswal AK: A unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin C. Br J Cancer. 2000 Apr;82(7):1305-11.
10874136	Floreani M, Napoli E, Palatini P: Protective action of cardiac DT-diaphorase against menadione toxicity in guinea pig isolated atria. Biochem Pharmacol. 2000 Aug 15;60(4):601-5.
10949919	Arriagada C, Dagnino-Subiabre A, Caviedes P, Armero JM, Caviedes R, Segura-Aguilar J: Studies of aminochrome toxicity in a mouse derived neuronal cell line: is this toxicity mediated via glutamate transmission? Amino Acids. 2000;18(4):363-73.
2113031	Preusch PC, Smalley DM: Vitamin K1 2,3-epoxide and quinone reduction: mechanism and inhibition. Free Radic Res Commun. 1990;8(4-6):401-15.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
NQO1

# Drug_Target_2_GenBank_ID_Gene:
J03934

# Drug_Target_2_GenBank_ID_Protein:
189246

# Drug_Target_2_GeneCard_ID:
NQO1

# Drug_Target_2_Gene_Name:
NQO1

# Drug_Target_2_Gene_Sequence:
>825 bp
ATGGTCGGCAGAAGAGCACTGATCGTACTGGCTCACTCAGAGAGGACCTCCTTCAACTAT
GCCATGAAGGAGGCTGCTGCAGCGGCTTTGAAGAAGAAAGGATGGGAGGTGGTGGAGTCG
GACCTCTATGCCATGAACTTCAATCCCATCATTTCCAGAAAGGACATCACAGGTAAACTG
AAGGACCCTGCGAACTTTCAGTATCCTGCCGAGTCTGTTCTGGCTTATAAAGAAGGCCAT
CTGAGCCCAGATATTGTGGCTGAACAAAAGAAGCTGGAAGCCGCAGACCTTGTGATATTC
CAGTTCCCCCTGCAGTGGTTTGGAGTCCCTGCCATTCTGAAAGGCTGGTTTGAGCGAGTG
TTCATAGGAGAGTTTGCTTACACTTACGCTGCCATGTATGACAAAGGACCCTTCCGGAGT
AAGAAGGCAGTGCTTTCCATCACCACTGGTGGCAGTGGCTCCATGTACTCTCTGCAAGGG
ATCCACGGGGACATGAATGTCATTCTCTGGCCAATTCAGAGTGGCATTCTGCATTTCTGT
GGCTTCCAAGTCTTAGAACCTCAACTGACATATAGCATTGGGCACACTCCAGCAGACGCC
CGAATTCAAATCCTGGAAGGATGGAAGAAACGCCTGGAGAATATTTGGGATGAGACACCA
CTGTATTTTGCTCCAAGCAGCCTCTTTGACCTAAACTTCCAGGCAGGATTCTTAATGAAA
AAAGAGGTACAGGATGAGGAGAAAAACAAGAAATTTGGCCTTTCTGTGGGCCATCACTTG
GGCAAGTCCATCCCAACTGACAACCAGATCAAAGCTAGAAAATGA

# Drug_Target_2_General_Function:
Involved in oxidoreductase activity

# Drug_Target_2_General_References:
10447260	Kristiansen OP, Larsen ZM, Johannesen J, Nerup J, Mandrup-Poulsen T, Pociot F: No linkage of P187S polymorphism in NAD(P)H: quinone oxidoreductase (NQO1/DIA4) and type 1 diabetes in the Danish population. DIEGG and DSGD. Danish IDDM Epidemiology and Genetics Group and The Danish Study Group of Diabetes in Childhood. Hum Mutat. 1999;14(1):67-70.
10706635	Faig M, Bianchet MA, Talalay P, Chen S, Winski S, Ross D, Amzel LM: Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3177-82.
1657151	Jaiswal AK: Human NAD(P)H:quinone oxidoreductase (NQO1) gene structure and induction by dioxin. Biochemistry. 1991 Nov 5;30(44):10647-53.
1737339	Traver RD, Horikoshi T, Danenberg KD, Stadlbauer TH, Danenberg PV, Ross D, Gibson NW: NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 1992 Feb 15;52(4):797-802.
2843525	Jaiswal AK, McBride OW, Adesnik M, Nebert DW: Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase. cDNA sequence and localization of gene to chromosome 16. J Biol Chem. 1988 Sep 25;263(27):13572-8.

# Drug_Target_2_HGNC_ID:
HGNC:2874

# Drug_Target_2_HPRD_ID:
00518

# Drug_Target_2_ID:
2157

# Drug_Target_2_Locus:
16q22.1

# Drug_Target_2_Molecular_Weight:
30868

# Drug_Target_2_Name:
NAD(P)H dehydrogenase [quinone] 1

# Drug_Target_2_Number_of_Residues:
274

# Drug_Target_2_PDB_ID:
1KBQ

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF02525	Flavodoxin_2

# Drug_Target_2_Protein_Sequence:
>NAD(P)H dehydrogenase [quinone] 1
MVGRRALIVLAHSERTSFNYAMKEAAAAALKKKGWEVVESDLYAMNFNPIISRKDITGKL
KDPANFQYPAESVLAYKEGHLSPDIVAEQKKLEAADLVIFQFPLQWFGVPAILKGWFERV
FIGEFAYTYAAMYDKGPFRSKKAVLSITTGGSGSMYSLQGIHGDMNVILWPIQSGILHFC
GFQVLEPQLTYSIGHTPADARIQILEGWKKRLENIWDETPLYFAPSSLFDLNFQAGFLMK
KEVQDEEKNKKFGLSVGHHLGKSIPTDNQIKARK

# Drug_Target_2_Reaction:
NAD(P)H + H+ + a quinone = NAD(P)+ + a hydroquinone

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinons involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis

# Drug_Target_2_SwissProt_ID:
P15559

# Drug_Target_2_SwissProt_Name:
NQO1_HUMAN

# Drug_Target_2_Synonyms:
Azoreductase
DT-diaphorase
DTD
EC 1.6.5.2
Menadione reductase
NAD(P)H:quinone oxidoreductase 1
Phylloquinone reductase
QR1
Quinone reductase 1

# Drug_Target_2_Theoretical_pI:
9.34

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasm

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
10561120	Evans PJ: Decreased intracellular proteolysis correlates with the maintenance of a specific isoenzyme of cytochrome P-450. Cell Biol Int. 1999;23(2):117-24.
12882764	Audi SH, Bongard RD, Dawson CA, Siegel D, Roerig DL, Merker MP: Duroquinone reduction during passage through the pulmonary circulation. Am J Physiol Lung Cell Mol Physiol. 2003 Nov;285(5):L1116-31. Epub 2003 Jul 25.
16700548	Asher G, Dym O, Tsvetkov P, Adler J, Shaul Y: The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol. Biochemistry. 2006 May 23;45(20):6372-8.
1722672	Maser E, Gebel T, Netter KJ: Carbonyl reduction of metyrapone in human liver. Biochem Pharmacol. 1991 Dec 11;42 Suppl:S93-8.
17305492	Hao H, Wang G, Cui N, Li J, Xie L, Ding Z: Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation. Curr Drug Metab. 2007 Feb;8(2):137-49.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
CRYZ

# Drug_Target_3_GenBank_ID_Gene:
L13278

# Drug_Target_3_GenBank_ID_Protein:
292415

# Drug_Target_3_GeneCard_ID:
CRYZ

# Drug_Target_3_Gene_Name:
CRYZ

# Drug_Target_3_Gene_Sequence:
>990 bp
ATGGCGACTGGACAGAAGTTGATGAGAGCTGTTAGAGTTTTTGAATTTGGTGGGCCAGAA
GTCCTGAAATTGCGATCAGATATTGCAGTACCGATTCCAAAAGACCATCAGGTTCTAATC
AAGGTCCATGCATGTGGTGTCAACCCCGTGGAGACATACATTCGCTCTGGTACTTATAGT
AGAAAACCACTCTTACCCTATACTCCTGGCTCAGATGTGGCTGGGGTGATAGAAGCTGTT
GGAGATAATGCATCTGCTTTCAAGAAAGGTGACAGAGTTTTCACTAGCAGCACGATCTCT
GGGGGTTATGCAGAGTATGCTCTTGCAGCAGACCACACTGTTTACAAACTACCTGAAAAA
CTGGACTTTAAACAAGGAGCTGCCATCGGCATTCCATATTTTACTGCTTATCGAGCTCTG
ATCCACAGTGCCTGTGTGAAAGCTGGAGAGAGTGTTCTGGTTCATGGGGCAAGTGGAGGA
GTTGGATTAGCAGCATGCCAAATTGCTAGAGCTTATGGCTTAAAGATTTTGGGCACTGCT
GGTACTGAGGAAGGACAAAAGATTGTTTTGCAAAATGGAGCCCATGAAGTGTTCAATCAC
AGAGAAGTGAATTACATTGATAAAATTAAGAAGTATGTTGGTGAGAAAGGAATTGATATA
ATTATTGAAATGTTAGCTAATGTAAATCTTAGTAAAGACTTGAGTCTTCTGTCACATGGA
GGACGAGTGATAGTTGTTGGCAGCAGAGGTACTATTGAAATAAACCCACGAGACACCATG
GCAAAGGAGTCGAGTATAATTGGAGTTACTCTCTTTTCCTCAACCAAGGAGGAATTTCAG
CAATATGCAGCAGCCCTTCAAGCTGGAATGGAAATTGGCTGGTTGAAACCTGTGATAGGT
TCTCAATATCCATTGGAGAAGGTGGCCGAGGCTCATGAAAATATCATTCATGGTAGTGGG
GCTACTGGAAAAATGATTCTTCTCTTATGA

# Drug_Target_3_General_Function:
Energy production and conversion

# Drug_Target_3_General_References:
8088825	Gonzalez P, Rao PV, Zigler JS Jr: Organization of the human zeta-crystallin/quinone reductase gene (CRYZ). Genomics. 1994 May 15;21(2):317-24.
8466529	Gonzalez P, Rao PV, Zigler JS Jr: Molecular cloning and sequencing of zeta-crystallin/quinone reductase cDNA from human liver. Biochem Biophys Res Commun. 1993 Mar 31;191(3):902-7.

# Drug_Target_3_HGNC_ID:
HGNC:2419

# Drug_Target_3_HPRD_ID:
00437

# Drug_Target_3_ID:
2159

# Drug_Target_3_Locus:
1p31-p22

# Drug_Target_3_Molecular_Weight:
35207

# Drug_Target_3_Name:
Quinone oxidoreductase

# Drug_Target_3_Number_of_Residues:
329

# Drug_Target_3_PDB_ID:
1YB5

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00107	ADH_zinc_N
PF08240	ADH_N

# Drug_Target_3_Protein_Sequence:
>Quinone oxidoreductase
MATGQKLMRAVRVFEFGGPEVLKLRSDIAVPIPKDHQVLIKVHACGVNPVETYIRSGTYS
RKPLLPYTPGSDVAGVIEAVGDNASAFKKGDRVFTSSTISGGYAEYALAADHTVYKLPEK
LDFKQGAAIGIPYFTAYRALIHSACVKAGESVLVHGASGGVGLAACQIARAYGLKILGTA
GTEEGQKIVLQNGAHEVFNHREVNYIDKIKKYVGEKGIDIIIEMLANVNLSKDLSLLSHG
GRVIVVGSRGTIEINPRDTMAKESSIIGVTLFSSTKEEFQQYAAALQAGMEIGWLKPVIG
SQYPLEKVAEAHENIIHGSGATGKMILLL

# Drug_Target_3_Reaction:
NADPH + H+ + quinone = NADP+ + semiquinone

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Does not have alcohol dehydrogenase activity. Binds NADP and acts through a one-electron transfer process. Orthoquinones are the best substrates. May act in the detoxification of xenobiotics

# Drug_Target_3_SwissProt_ID:
Q08257

# Drug_Target_3_SwissProt_Name:
QOR_HUMAN

# Drug_Target_3_Synonyms:
EC 1.6.5.5
NADPH:quinone reductase
Zeta- crystallin

# Drug_Target_3_Theoretical_pI:
8.70

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB00266
